Audit Opinion - The audit report states that the financial statements of Tibet Kangyu Pharmaceutical Co., Ltd. fairly reflect its financial position as of December 31, 2024, and April 30, 2025, in accordance with accounting standards [2][3]. Company Overview - Tibet Kangyu Pharmaceutical Co., Ltd. was established on March 18, 2015, with a registered capital of RMB 10 million, fully paid [5]. - The company operates in the wholesale industry, primarily engaged in the sale of pharmaceuticals and medical devices, along with various other products [5]. Financial Reporting Basis - The financial statements are prepared based on the going concern assumption, indicating that the company has the ability to continue its operations for at least the next 12 months [6]. - The financial statements comply with the requirements of the accounting standards, providing a true and complete reflection of the company's financial status, operating results, and cash flows [6]. Accounting Policies and Estimates - The company uses the perpetual inventory system for its inventory management, valuing inventory at actual cost upon acquisition [22]. - The company recognizes financial assets and liabilities based on their classification, including those measured at amortized cost and those measured at fair value [10][12]. Financial Instruments - Financial assets are classified based on the business model for managing them and their contractual cash flow characteristics [6][10]. - The company applies the expected credit loss model for impairment accounting, assessing credit risk based on historical experience and current conditions [16][19]. Long-term Investments - Long-term equity investments are accounted for using the cost method for subsidiaries and the equity method for joint ventures and associates [26][27]. - The company evaluates its long-term investments based on the fair value of the underlying assets and adjusts the carrying amount accordingly [24][28].

Group 1 - The company announced a share repurchase plan with a total expected amount between 70 million and 131.58 million RMB, with a repurchase price not exceeding 7.31 RMB per share [1] - The repurchase period is set from March 14, 2025, to March 14, 2026, and the shares will be used for the 2025 restricted stock incentive plan [1] - As of July 31, 2025, the company has repurchased a total of 16.299951 million shares, accounting for 1.25% of the total share capital, with a total expenditure of 80.2576 million RMB [2] Group 2 - The highest repurchase price recorded was 5.22 RMB per share, while the lowest was 4.69 RMB per share [2] - The total share capital increased from 1,308,916,414 shares at the end of June 2025 to 1,308,927,729 shares at the end of July 2025 due to the conversion of the company's convertible bonds [2] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [2]

Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. has approved the use of up to 700 million yuan of temporarily idle raised funds for cash management, investing in low-risk, high-liquidity principal-protected financial products [1] Group 1: Cash Management Approval - The board of directors and the supervisory board approved the cash management proposal during meetings held from January 20 to 22, 2025 [1] - The cash management usage period is valid for 12 months from the date of board approval, with the option for rolling use [1] Group 2: Redemption and Returns - Fujian Tongchun used 40 million yuan of temporarily idle funds to purchase a structured deposit from China Merchants Bank, which matured on July 31, 2025, yielding a return of 46,000 yuan [2] - The principal and returns from the structured deposit have been returned to the dedicated fundraising account [2] Group 3: Recent Cash Management Activities - In the last 12 months, the company has invested a total of 202.9 million yuan in various cash management products, with a total return of 227,490 yuan [3] - The highest single-day investment in the last 12 months was 70 million yuan, representing 10.24% of the audited net assets for the past year [3] Group 4: Current Cash Management Status - The total cash management limit is 70 million yuan, with 46.2 million yuan already utilized and 23.8 million yuan remaining available for use [4]

Core Viewpoint - Nanjing Pharmaceutical announced the completion of a share buyback program, having repurchased a total of 16,299,951 shares as of July 31, 2025 [2] Summary by Relevant Sections - **Company Actions** - The company has executed a share buyback through centralized bidding, accumulating a total of 16,299,951 shares [2] - **Timeline** - The share buyback program is set to conclude on July 31, 2025 [2]

证券之星消息，8月1日医药商业板块较上一交易日上涨1.43%，达嘉维康领涨。当日上证指数报收于 3559.95，下跌0.37%。深证成指报收于10991.32，下跌0.17%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 603883 | 老百姓 | 19.21 | -1.49% | | 18.34万 | 3.54Z | | 301015 | 百洋医药 | 21.97 | -0.45% | | 10.05万 | 2.22亿 | | 600829 | 人民同泰 | 8.30 | 0.24% | | 18.88万 | 1.57亿 | | 600056 | 中国医药 | 11.08 | 0.36% | | 30.82万 | 3.43亿 | | 000950 | 重药控股 | 5.32 | 0.57% | | 20.35万 | 1.09亿 | | 603233 | 大参林 | 17.42 | 0.64% | | 4.04万 | 7047.76万 | | 6 ...

Core Viewpoint - Nanjing Pharmaceutical (600713.SH) has repurchased a total of 16.299951 million shares, representing 1.25% of the total share capital as of July 31, 2025 [1] Summary by Category Share Repurchase - The company has conducted share repurchases through centralized bidding, with no change in the cumulative number of shares repurchased compared to the last disclosure [1] - The highest price for the repurchased shares was 5.22 CNY per share, while the lowest price was 4.69 CNY per share [1] - The total amount of funds paid for the repurchase, excluding transaction fees, was 80.2576 million CNY [1]

本文源自：金融界 最近三个交易日，29日-31日，华人健康分别获融资买入0.17亿元、0.53亿元、0.22亿元。 融券方面，当日融券卖出0.00万股，净买入0.01万股。 7月31日，沪深两融数据显示，华人健康获融资买入额0.22亿元，居两市第1770位，当日融资偿还额0.22 亿元，净买入69.82万元。 作者：智投君 ...

Group 1 - The closing price of Saily Medical on July 31 was 30.02 yuan, down 2.82% from the previous trading day, with significant intraday volatility, reaching a high of 32.00 yuan and a low of 29.38 yuan, resulting in an amplitude of 8.48% and a trading volume of 1.242 billion yuan [1] - Saily Medical operates in the pharmaceutical commercial sector, focusing on the research, production, and sales of in vitro diagnostic reagents and instruments, as well as providing centralized operation services [1] - The company's product range includes biochemical, immunological, and molecular diagnostics, serving medical institutions and laboratories [1] Group 2 - On July 31, Saily Medical experienced a net outflow of main funds amounting to 75.5931 million yuan, which represents 1.32% of its circulating market value [2]

第二条 本办法所称募集资金是指，公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金。 国药集团药业股份有限公司 募集资金使用管理办法 （已经公司 2025 年 7 月 31 日第八届董事会第二十七次会议审议通过，尚需 2025 年第二次临时股东大会审议） 第一章 总则 第一条 为了规范国药集团药业股份有限公司（以下简称"公司"）募集资 金的管理和使用，保护投资者的利益，依据《中华人民共和国公司法》《中华人 民共和国证券法》《上市公司募集资金监管规则》《上海证券交易所上市公司自 律监管指引第 1 号——规范运作》《上海证券交易所股票上市规则》等法律、法 规及《国药集团药业股份有限公司章程》规定，结合公司实际情况，特制定本办 法。 本办法所称超募资金是指实际募集资金净额超过计划募集资金金额的部分。 第三条 募集资金只能用于公司对外披露的募集资金投资项目（以下简称 "募投项目"）。募集资金的管理应遵循规范、安全、高效、透明的原则。 第四条 公司建立募集资金存储、使用和管理的内部控制制度，对募集资金 存储、使用、变更、监督和责任追究以及募集资金使用的申请、分级审批权限、 决策程序、风险控制 ...

国药集团药业股份有限公司 关联交易管理办法 （已经公司 2025 年 7 月 31 日第八届董事会第二十七次会议审议通过，尚需 2025 年第二次临时股东大会审议） 第一章 总则 第一条 为进一步规范国药集团药业股份有限公司（以下简称"公司"）及 控股子公司与关联方的资金往来和关联交易，根据《中华人民共和国公司法》 《中 华人民共和国证券法》《上市公司独立董事管理办法》《上海证券交易所股票上 市规则》《上市公司信息披露管理办法》及《上海证券交易所上市公司自律监管 指引第 5 号——交易与关联交易》等相关法律法规的要求，以及《国药集团药业 股份有限公司章程》（以下简称"《公司章程》"）等有关规定，制定本办法。 第二条 公司的关联交易应当遵循以下基本原则： （一）符合诚实信用及公平、公正、公开的原则； （二）关联交易应当做到合理必要、定价公允、决策程序合规、信息披露规 范，保持公司的独立性，符合公司的利益，不得损害公司和非关联股东的利益； （三）在对关联交易进行决策时，关联股东及关联董事应妥善遵守相关法律 法规、 《公司章程》及本办法规定的回避制度及其他保障关联交易公允性的措施。 第三条 公司董事会及独立董事专门 ...